- Home
- RELX vs GNLX Comparison
RELX vs GNLX Comparison
Compare RELX & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RELX | GNLX |
|---|---|---|
| Founded | 1903 | 2001 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.3B | 202.4M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | RELX | GNLX |
|---|---|---|
| Price | $40.30 | $4.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | N/A | ★ $19.75 |
| AVG Volume (30 Days) | ★ 2.3M | 195.5K |
| Earning Date | 07-24-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | ★ 3.29 | N/A |
| EPS | ★ 1.42 | N/A |
| Revenue | ★ $13,062,063,298.00 | N/A |
| Revenue This Year | $6.07 | N/A |
| Revenue Next Year | $6.60 | N/A |
| P/E Ratio | $28.51 | ★ N/A |
| Revenue Growth | ★ 2.48 | N/A |
| 52 Week Low | $39.31 | $1.99 |
| 52 Week High | $56.33 | $8.54 |
Technical Indicators
Market Signals| Indicator | RELX | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 35.71 |
| Support Level | $39.40 | $4.37 |
| Resistance Level | $40.76 | $4.75 |
| Average True Range (ATR) | 0.35 | 0.42 |
| MACD | 0.22 | -0.04 |
| Stochastic Oscillator | 64.21 | 8.99 |
Price Performance
Historical ComparisonAbout RELX RELX PLC PLC
RELX is a global provider of information-based analytics and decision tools for professional and business customers in various industries. The company serves sectors such as science and medical research, risk management, and legal. In addition, RELX organizes large-scale digital and face-to-face events such as industry trade shows. Around 60% of revenue is generated in North America and about 20% in Europe.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.